Renal Effects of Levosimendan in Cardiac Surgery Patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité - University Medicine Berlin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing cardiac surgery (OPS 5-35 bis 5-37) between 2007 and 2011 followed by postoperative observation on an ICU of the anaesthesiology department of the Charité hospital
Exclusion Criteria:
- Patients younger 18
- Preexisting renal insufficiency
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Levosimendan
study group
|
|
No Levosimendan
Control group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of plasma creatinine (Difference in renal function)
Time Frame: last available value pre-op (baseline), first available value on post-op day 1, 2, 3 and 4
|
Only in patients not requiring renal replacement therapy
|
last available value pre-op (baseline), first available value on post-op day 1, 2, 3 and 4
|
|
Change of urine output after surgery (difference in renal function)
Time Frame: post-op day 1, 2, 3, 4
|
Only in patients not requiring renal replacement therapy
|
post-op day 1, 2, 3, 4
|
|
Cumulative incidence and duration of hemodialysis (Difference in renal function)
Time Frame: last day of hospital stay
|
last day of hospital stay
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cumulative Length of stay (hospital and ICU)
Time Frame: last day of hospital stay
|
last day of hospital stay
|
|
In-hospital mortality
Time Frame: last day of hospital stay
|
last day of hospital stay
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi: 10.1186/cc5713.
- Yakut N, Yasa H, Bahriye Lafci B, Ortac R, Tulukoglu E, Aksun M, Ozbek C, Gurbuz A. The influence of levosimendan and iloprost on renal ischemia-reperfusion: an experimental study. Interact Cardiovasc Thorac Surg. 2008 Apr;7(2):235-9. doi: 10.1510/icvts.2007.161356. Epub 2007 Dec 3.
- Balzer F, Treskatsch S, Spies C, Sander M, Kastrup M, Grubitzsch H, Wernecke KD, Braun JP. Early administration of levosimendan is associated with improved kidney function after cardiac surgery - a retrospective analysis. J Cardiothorac Surg. 2014 Nov 18;9:167. doi: 10.1186/s13019-014-0167-8.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EA1-044-13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.